Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study
| Autor: | Andrea Nava, William J. McKenna, Cristina Basso, Fulvio Camerini, Michael J. Davies, Fontaliran F, Domenico Corrado, Guy Fontaine, Gaetano Thiene, Furio Silvestri, Carina Blomström-Lundqvist, Elżbieta K. Włodarska |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Pathology Adolescent Cardiomyopathy Desmoglein-2 Sudden death Right ventricular cardiomyopathy Naxos disease Electrocardiography Internal medicine Medicine Humans cardiovascular diseases Child Arrhythmogenic Right Ventricular Dysplasia Aged DSC2 business.industry Myocardium Arrhythmias Cardiac Middle Aged medicine.disease Arrhythmogenic right ventricular dysplasia Death Sudden Cardiac Dysplasia cardiovascular system Cardiology Disease Progression Female business Cardiology and Cardiovascular Medicine |
| Zdroj: | Journal of the American College of Cardiology. 30(6) |
| ISSN: | 0735-1097 |
| Popis: | Objectives. The aim of the present investigation was to redefine the clinicopathologic profile of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC), with special reference to disease progression and left ventricular (LV) involvement.Background. Long-term follow-up data from clinical studies indicate that ARVC is a progressive heart muscle disease that with time may lead to more diffuse right ventricular (RV) involvement and LV abnormalities and culminate in heart failure.Methods. Forty-two patients (27 male, 15 female; 9 to 65 years old, mean [±SD] age 29.6 ± 18) from six collaborative medical centers, with a pathologic diagnosis of ARVC at autopsy or heart transplantation, and with the whole heart available, were studied according to a specific clinicomorphologic protocol.Results. Thirty-four patients died suddenly (16 during effort); 4 underwent heart transplantation; 2 died as a result of advanced heart failure; and 2 died of other causes. Sudden death was the first sign of disease in 12 patients; the other 30 had palpitations, with syncope in 11, heart failure in 8 and stroke in 3. Twenty-seven patients experienced ventricular arrhythmias (ventricular tachycardia in 17), and 5 received a pacemaker. Ten patients had isolated RV involvement (group A); the remaining 32 (76%) also had fibrofatty LV involvement that was observed histologically only in 15 (group B) and histologically and macroscopically in 17 (group C). Patients in group C were significantly older than those in groups A and B (39 ± 15 years vs. 20 ± 8.8 and 25 ± 9.7 years, respectively), had significantly longer clinical follow-up (9.3 ± 7.3 years vs. 1.2 ± 2.1 and 3.4 ± 2.2 years, respectively) and developed heart failure significantly more often (47% vs. 0 and 0, respectively). Patients in groups B and C had warning symptoms (80% and 87%, respectively, vs. 30%) and clinical ventricular arrhythmias (73% and 82%, respectively, vs. 20%) significantly more often than patients in group A. Hearts from patients in group C weighed significantly more than those from patients in groups A and B (500 ± 150 g vs. 328 ± 40 and 380 ± 95 g, respectively), whereas hearts from both group B and C patients had severe RV thinning (87% and 71%, respectively, vs. 20%) and inflammatory infiltrates (73% and 88%, respectively, vs. 30%) significantly more often than those from group A patients.Conclusions. LV involvement was found in 76% of hearts with ARVC, was age dependent and was associated with clinical arrhythmic events, more severe cardiomegaly, inflammatory infiltrates and heart failure. ARVC can no longer be regarded as an isolated disease of the right ventricle. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|